Anti‐tumoral effects of low molecular weight heparins: A focus on the treatment of esophageal cancer

• Published in: Journal of cellular physiology Vol. 233; no. 10; pp. 6523 - 6529
• Main Authors: Javadinia, Seyed Alireza, Gholami, Arezoo, Joudi Mashhad, Mona, Ferns, Gordon A., Shahidsales, Soodabeh, Avan, Amir, Kermani, Ali Taghizadeh
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.10.2018
• Subjects: Angiogenesis; Anticoagulants; anti‐tumoral effects; Cancer; Esophageal cancer; Esophagus; Health risk assessment; Heparin; Immunomodulation; LMWH; low molecular weight heparin; Low molecular weights; Molecular chains; Molecular weight; Survival; low molecular weight heparin; LMWH; esophageal cancer; anti-tumoral effects
• ISSN: 0021-9541; 1097-4652
• DOI: 10.1002/jcp.26613

Esophageal cancer is one of the most prevalent types of cancer globally. With current treatment options, the survival is poor, and there are ongoing efforts to find new and more efficient therapeutic approaches. There are several reports on the anti‐tumoral effects of low‐molecular‐weight heparins (LMWH). We have assessed the possible survival benefits and underlying mechanisms of LMWHs in malignancies with a focus on esophageal cancer. We conclude that the effects of LMWHs on survival of cancer patients is probably due to a combination of direct anti‐tumoral, anti‐angiogenic, and immunomodulatory effects and indirect effects on the coagulation system. LMWHs have potential effects on survival of cancer patients that is probably due to a combination of direct anti‐tumoral, antiangiogenic, and immunomodulatory effects and indirect effects on the coagulation system.